Oramed Pharmaceuticals
ORMP
31 hedge funds and large institutions have $1.97M invested in Oramed Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
3% more funds holding
Funds holding: 30 → 31 (+1)
6% more call options, than puts
Call options by funds: $583K | Put options by funds: $550K
0.82% less ownership
Funds ownership: 3.59% → 2.77% (-0.82%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
39% less capital invested
Capital invested by funds: $3.21M → $1.97M (-$1.25M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$315K |
| 2 |
IAM
ICM Asset Management
Spokane,
Washington
|
+$171K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$162K |
| 4 |
Millennium Management
New York
|
+$57.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$32.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$196K |
| 2 |
Renaissance Technologies
New York
|
-$172K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$159K |
| 4 |
Morgan Stanley
New York
|
-$73.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$59.7K |
ORMP Hedge Fund Activity: Q1 2020 in Review
31 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2020, worth a combined $1.97M — down 39% from $3.21M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ORMP positions and 4 closed out — a net gain of 4 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Frontier Wealth Management, opening a new position worth an estimated $315K. The largest seller was Jane Street, exiting entirely with an estimated $196K sold.
- 31 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2020, up from 30 in Q4 2019.
- Funds reported $1.97M of Oramed Pharmaceuticals stock for Q1 2020, down 39% quarter-over-quarter.
- 8 funds opened new Oramed Pharmaceuticals positions in Q1 2020 and 4 closed out, a net change of +4 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2020 was Frontier Wealth Management, an estimated $315K added.
- The largest Oramed Pharmaceuticals seller in Q1 2020 was Jane Street, an estimated $196K sold.
Based on aggregated 13F filings for Q1 2020.